NPI 1003818147: Open Payments
NPI 1003818147. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$413 in 20 payments from 13 companies in 2025. Trend: 2023 $556 · 2024 $476 · 2025 $413
Food & beverage: $413
| Company | Payments | Amount |
|---|---|---|
| UROGEN PHARMA, INC. | 4 | $111 |
| TOLMAR, INC. | 3 | $56 |
| Dendreon Pharmaceuticals LLC | 2 | $49 |
| Sumitomo Pharma America, Inc. | 2 | $34 |
| Procept Biorobotics Corporation | 1 | $24 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $21 |
| Merck Sharp & Dohme LLC | 1 | $20 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
| Calyxo, Inc. | 1 | $17 |
| Novartis Pharmaceuticals Corporation | 1 | $17 |
Products named: JELMYTO, PROVENGE, JATENZO, ZUSDURI, AQUABEAM ROBOTIC SYSTEM, Nubeqa, KEYTRUDA, GEMTESA.
